Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
LIDE Biotech provides advanced preclinical contract research services with a focus on oncology. Their offerings include over 2000 patient-derived xenograft (PDX) models across more than 50 cancer types—including drug-resistant/genetically altered variants—MiniPDX rapid efficacy testing platform delivering results in seven days, conditionally reprogrammed cell lines maintaining tumor heterogeneity, CDX models for cost-effective in vivo studies, comprehensive omics/bioanalysis capabilities (genomics/transcriptomics/proteomics), and robust immuno-oncology model systems. The company has delivered thousands of projects globally over its 12-year history[1][2][4][5].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on LIDE Biotech.